Increasingly, the great new medical technologies aren’t coming from the pharmaceutical behemoths, but from scrappy little biotech upstarts. In few instances is this truer than in the field of cancer immunotherapy.
Immunotherapy is defined as a “treatment designed to produce immunity to disease or enhance the resistance of the immune system to an active disease process, as cancer.” Simply put, cancer immunotherapy activates the body’s powerful and complex immune system so that it can do its job better.
Immune system-based therapies are becoming a proven route to improving cancer treatment. There are multiple immunotherapy innovators, several of which have performed well in our Technology Profits Confidential portfolio due to their deep and diverse developmental pipelines.
Some immune-based therapies work, for example, by training the immune system to identify and attack cancer cells. Functionally, therefore, they are vaccines.
Others use antibodies to achieve similar results. Antibodies are an important part of our natural biological defenses. They are used by the immune system to identify infectious microbes and mutant cancer cells. Once these foreign objects are flagged by antibodies, other immune system components, such as white blood cells, move in for the kill.
ADC (antibody-drug conjugation) technology, for example, works by combining an immune system component — antibodies — with a toxic payload.
ADC technology uses engineered antibodies to target molecular markers that are overexpressed on cancer cells, yet absent or uncommon on healthy ones. The attached toxin is then released to kill the cell.
Another kind of ADC technology doesn’t link antibodies directly to cancer cells, but instead, attach an antigen to an antibody that is targeted to attach to antigen-presenting cells (APCs) — specifically, dendritic cells. Once attached to a dendritic cell, it presents an antigen that’s frequently present in a wide variety of cancer types, including sarcoma, myeloma, melanoma and cancer of the bladder, breast, ovaries and lungs.
Many antibody-based cancer immunotherapy companies imitate this natural defense mechanism by creating custom antibodies to home in on molecular targets present on cancer cells. Once an immune system cell, such as a T-cell, comes into contact with an attached antibody, it attacks the tagged cancer cell.
Then there’s technology that uses compounds that aren’t antibodies, but protein that stimulates the immune system by proliferating and mobilizing bone marrow stem cells and immune cells.
When choosing different companies that specialize in this kind of technology, many factors come into play. But when picking companies undergoing trials, it’s better to go with fully human antibody therapeutics over “humanized” mouse (or any other animal) antibody.
When it’s fully human, it should be better tolerated by human patients. Humans can have an immune reaction to nonhuman antibodies, paradoxically producing their own antibodies to the therapeutic antibody. This causes the patient’s immune system to destroy the therapeutic antibodies.
This can reduce the effectiveness of an antibody therapy and require more frequent dosing. And because antibody drugs are large proteins that must be administered through injection, the frequency of dosing is important to patients.
Takeaway: keep these kinds of immunotherapy approaches in mind when looking for biotech companies with high growth potential.
Ad lucrum per scientia (toward wealth through science),
Think back to Star Wars... Imagine the Death Star becoming a reality... But instead of a force for destruction, imagine that the energy harnessed from such a satellite could power an entire planet. Well, in a little over ten years, you might be able to witness it for yourself. Here's how...
In 8th grade Ray Blanco was in his basement learning how to build what's called a "Wilson Cloud Chamber," a supercooled device for detecting particles of ionizing radiation. Now, he is an expert in advanced robotics, avionics, genomics, and biotechnology. Blanco was raised in Miami,FL, after his family fled Cuba in the 1960s. He is co-editor of Technology Profits Confidential and contributes to Breakthrough Technology Alert and Tomorrow in Review.
Pingback: garcinia cambogia supplement
Pingback: what is may day
Pingback: auto insrance rates
Pingback: auto insurance calculator
Pingback: motorcycle resources
The big problem with declaring bubbles is that it really does you no good. Unless you're attempting to measure and time market moves, you're also blowing hot air. But if you keep watch for negative divergences, you have a much better shot at figuring out big market moves than the latest bubble-busters. Greg Guenthner explains...
Oil isn't the only resource to experience "peaks." Due to a major contraction in gold exploration over the past few years, the mining sector is no longer mining gold at its replacement rate. In other words, the amount of gold above ground is running out. And according to Henry Bonner, it will get worse before it gets better...
Too often investments are made in a vacuum. But as Byron King demonstrates, the global economic crash... easy money... and technological advancements are all interdependent. In particular, that connection has changed the investment calculus in the resource market. Read on to learn how...
Back in the 1980s, John Nestor became infamous for single-handedly causing massive traffic jams on the Capital Beltway. But in his professional life, he created a completely different kind of traffic jam... one that may have contributed to the deaths of thousands of innocent people. Juan Enriquez has the full story. Read on...
Too many people think that long-term care planning is just a decision about whether to purchase long-term care insurance. However, long-term care planning is so much more... It is a discussion about how you will fund this expense, where you will receive long-term care, and who will provide the care. Jamie Hopkins explains...